Douglas Matsunaga
Ophthalmology · Los Angeles, CANPI 1821450818
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,738 of the $9,115 with a category attached, or 62.9%. AbbVie accounts for 73.3% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $7,049, more than ten times the $144 reported in 2020.
Across 69 payments — averaging $132.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Apellis Pharmaceuticals, Inc.$682
- Regeneron Healthcare Solutions, Inc.$379
- Genentech USA, Inc.$287
- Alcon$278
- Alimera Sciences, Inc.$250
- plus $561 from 7 others
What the payments were for
- Consulting fees$5,73863%
- Travel & lodging$3474%
- Food & beverage$3,03033%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $6,678 |
| Apellis Pharmaceuticals, Inc. | 12 | $682 |
| Regeneron Healthcare Solutions, Inc. | 4 | $379 |
| Genentech USA, Inc. | 11 | $287 |
| Alcon | 3 | $278 |
| Alimera Sciences, Inc. | 2 | $250 |
| Eyepoint US, Inc. | 1 | $149 |
| Glaukos Corporation | 1 | $125 |
| Bausch & Lomb Americas Inc. | 2 | $121 |
| Neurotech Pharmaceuticals, Inc. | 1 | $110 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Amgen | 1 | $19 |
| Biogen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iluvien$250
- Constellation$247
- Syfovre$157
- YUTIQ$149
- iStent inject Trabecular Micro-Bypass Stent System$125
- EYLEA$125
- EYLEA HD$120
- MIEBO$101
How this compares
$9,115 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 147 | $5,222 |
| Brimonidine Tartrate | 51 | $2,539 |
| Ketorolac Tromethamine | 61 | $1,770 |
| Atropine Sulfate | 25 | $655 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 44 | $651 |
| Latanoprost | 92 | $626 |
| MoxifloxacinMoxifloxacin Hcl | 27 | $483 |
| Ofloxacin | 38 | $366 |
| Dorzolamide Hcl | 18 | $303 |
| Timolol Maleate | 22 | $127 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Los Angeles
- Andrew MoshfeghiLos Angeles$895K
- Barry SeibelLos Angeles$835K
- Nicole FramLos Angeles$551K
- Neda ShamieLos Angeles$547K
- David BoyerLos Angeles$406K
- David HamiltonLos Angeles$359K
- Arjan HuraLos Angeles$306K
- Firas RahhalLos Angeles$264K
- Kouros NourimahdaviLos Angeles$258K
- Daniel RootmanLos Angeles$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.